

Clinical Updates in Urothelial Carcinoma from Madrid

Clinical Update #1 – First-Line Therapy for Patients With LA/mUC, Irrespective of Cisplatin Eligibility

References

Tweet 2 References:

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): bladder cancer (v3.2023). Updated May 25, 2023. Accessed October 25, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. *N Engl J Med*. 2020;383(13):1218-1230. doi:10.1056/NEJMoa2002788

Powles T, Park SH, Caserta C, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after ≥2 years of follow-up. *J Clin Oncol*. 2023;41(19):3486-3492. doi:10.1200/JCO.22.01792

Powles T, Perez Valderrama, B, Gupta S, et al. Open-label, randomized phase 3 study of enfortumab vedotin in combination with pembrolizumab vs chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma. Abstract presented at: 2023 ESMO Congress 2023; October 22, 2023; Madrid, Spain. Abstract LBA6.

van der Heijden M, Sonpavde G, Powles T, et al. Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial. Abstract presented at: 2023 ESMO Congress 2023; October 22, 2023; Madrid, Spain. Abstract LBA7.

van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. *N Engl J Med*. Published online October 22, 2023. doi:10.1056/NEJMoa2309863

Additional References:

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): bladder cancer (v3.2023). Updated May 25, 2023. Accessed October 25, 2023.

https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. *N Engl J Med*. 2020;383(13):1218-1230. doi:10.1056/NEJMoa2002788

Powles T, Park SH, Caserta C, et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after ≥2 years of follow-up. *J Clin Oncol*. 2023;41(19):3486-3492. doi:10.1200/JCO.22.01792

Powles T, Perez Valderrama, B, Gupta S, et al. Open-label, randomized phase 3 study of enfortumab vedotin in combination with pembrolizumab vs chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma. Abstract presented at: 2023 ESMO Congress 2023; October 22, 2023; Madrid, Spain. Abstract LBA6.

van der Heijden M, Sonpavde G, Powles T, et al. Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial. Abstract presented at: 2023 ESMO Congress 2023; October 22, 2023; Madrid, Spain. Abstract LBA7.

van der Heijden MS, Sonpavde G, Powles T, et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. *N Engl J Med*. Published online October 22, 2023. doi:10.1056/NEJMoa2309863

Apolo A. Invited discussant LBA6 and LBA7. Lecture presented at: 2023 ESMO Congress; October 22, 2023; Madrid, Spain.

Pace A, Brower B, Conway D, Leis D. Enfortumab vedotin: nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma. *Clin J Oncol Nurs*. 2021;25(2):E1-E9. doi:10.1188/21.CJON.E1-E9

Glossary

1L, first line
AE, adverse event
BSC, best supportive care
cis, cisplatin
CM901, CheckMate 901
CME, continuing medical education
CT, chemotherapy
ESMO, European Society for Medical Oncology
EV, enfortumab vedotin
EV+P, enfortumab vedotin + pembrolizumab
gem, gemcitabine
HR, hazard ratio
LA/mUC, locally advanced or metastatic urothelial carcinoma
m, metastatic
mUC, metastatic urothelial carcinoma
NCCN, National Comprehensive Cancer Network
nivo, nivolumab
NP, nurse practitioner
ORR, overall response rate
OS, overall survival
PA, physician assistant
PD-L1, programmed death-ligand 1
PFS, progression-free survival
PS, performance status
pts, patients
trAE, treatment-related adverse event
tx, therapy
UC, urothelial carcinoma
w/, with
yo, year old